GIUBILATO S

Thienopyridines have a well-established role in the treatment of coronary artery disease, especially in the setting of acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was shown to be effective in reducing coronary events in high risk patients, but the original enthusiasm was...

No description

Aims Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results A...

Objective To assess the clinical outcome of unselected patients undergoing drug-eluting stent (DES) implantation on bifurcated lesions using a provisional T And small Protrusion (TAP) stenting strategy Methods Consecutive patients undergoing DES implantation on one major bifurcation lesion were treated by main-vessel (MV) stenting followed (if...

High levels of thromboxane A2 (TxA2), a key mediator of platelet activation and aggregation, are associated with an increased risk of cardiovascular events. We aimed at assessing the predictors of higher plasma levels of Tx82, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome...